Insitro's chief executive outlines strategies for using artificial intelligence to shorten drug trials
In an interview, Insitro's Daphne Koller explained how artificial intelligence can streamline clinical trial processes and reduce delays. The discussion also covered broader applications of AI in health care.
Related stories
Faro AI lands $37M to streamline clinical trial operations · Drug development
Debate over optimal cancer drug dosing intensifies · Cancer research
PBMs agree to show TrumpRx pricing · Healthcare systems
Upcoming readouts expected for experimental cardiovascular drug class · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: AI biotech Insitro’s Daphne Koller on how to speed up clinical trials.” Browse more stories.